4D Pharma PLC (LBPS) stock Surges Premarket on Positive Interim Results from its Cancer Study
4D Pharma PLC (LBPS) stock Surges Premarket on Positive Interim Results from its Cancer Study
The company is conducting its Phase I/II study of the combination of MRx0518 and KEYTRUDA® in three tumor groups along with RCC. The study is being conducted in collaboration with MSD (Merck Co., Inc., Kenilworth, NJ, USA). Moreover, the study is conducted in heavily pre-treated metastatic patients with solid tumors with progressive disease.On March 23, 4D Pharma PLC (LBPS) announced positive interim results from the Phase I/II study for the treatment of Renal Cell Carcinoma (RCC). Consequently, the stock surged up in the premarket and was trading at $6.13 at the last check.
3月23日，4D Pharma PLC(LBPS)宣佈了治療腎癌(RCC)的I/II期研究的積極中期結果。因此，該股在盤前飆升，在最後一次檢查時交易價格為6.13美元。
In the previous trading session on Tuesday, the stock remained in the green with a gain of 7.67%. LBPS fluctuated between a high of $4.75 and a low of $7.57 at a volume of 12.72K shares. At the close of the session, the stock had a value of $4.66 per share while the volume of shares traded remained below the average. Following the news, the stock had surged up by 31.29% at the time of writing, in the premarket on Wednesday.
在週二的前一個交易日，該股仍保持綠色，漲幅為7.67%。LBPS在4.75美元的高點和7.57美元的低點之間波動，成交量為12.72萬股。收盤時，該股每股價值4.66美元，而成交量仍低於平均水平。消息傳出後，在週三的盤前交易中，截至撰寫本文時，該股已飆升31.29%。
The UK-based pharmaceutical company, 4D Pharma PLC develops live biotherapeutics. Founded in 2014, the company has a market capitalization of $95.71 million with its 22.54 million outstanding shares. Standing at a year-to-date loss of 14.33%, LBPS subtracted a value of 62.86% in the past year.
這家總部位於英國的製藥公司4D Pharma PLC開發活的生物療法。該公司成立於2014年，擁有2254萬股流通股，市值為9571萬美元。LBPS今年迄今的虧損為14.33%，減去了過去一年的62.86%。
LBPS' RCC Interim Data
LBPS的RCC中期數據
The company is conducting its Phase I/II study of the combination of MRx0518 and KEYTRUDA® in three tumor groups along with RCC. The study is being conducted in collaboration with MSD (Merck Co., Inc., Kenilworth, NJ, USA). Moreover, the study is conducted in heavily pre-treated metastatic patients with solid tumors with progressive disease.
該公司正在對MRx0518和KEYTRUDA®在三個腫瘤組以及腎癌中的組合進行I/II期研究。這項研究是與MSD(默克公司，美國新澤西州凱尼爾沃斯)合作進行的。此外，這項研究是在經過大量治療的轉移性腫瘤患者中進行的，這些患者的實體腫瘤呈進展性疾病。
MRx0518 is LBPS' microbiome for cancer treatment while KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp. (a subsidiary of Merck and Kenilworth).
MRx0518是LBPS用於癌症治療的微生物組，而KEYTRUDA®是默克·夏普·多姆公司(Merck Sharp&Dohme Corp.)(默克和凱尼爾沃斯的子公司)的註冊商標。
Today, LBPS reported positive interim data from the RCC group of the study. According to this, the RCC group has met its primary efficacy endpoint before the completion of patient enrollment.
今天，LBPS報告了來自研究的RCC小組的積極的中期數據。根據這一點，RCC組在患者登記完成之前已經達到了其主要療效終點。
Additionally, the company will be hosting a conference call and live webcast today at 10:00 am EST for discussing the interim results.
此外，該公司將在美國東部時間今天上午10：00主持電話會議和網絡直播，討論中期業績。
Recent Participations
最近的參與情況
Recently, the company participated in the Chardan Metagenomics and Microbiome Medicines Summit. LBPS CEO Duncan Peyton and CSO Alex Stevenson participated in a fireside chat at the conference on March 1, 2022.
近日，該公司參加了查爾丹元基因組學和微生物組藥物峯會。LBPS首席執行官鄧肯·佩頓和CSO亞歷克斯·史蒂文森在2022年3月1日的會議上參加了爐邊聊天。
Before that, Mr. Peyton and Mr. Stevenson also presented at the H.C. Wainwright BioConnect Conference on January 10, 2022.
在此之前，佩頓先生和史蒂文森先生還於2022年1月10日在H.C.Wainwright BioConneCT大會上發表了演講。
LBPS' Latest INDs
LBPS的最新索引
On February 22, the company announced the IND clearance of two Live Biotherapeutics (LBPs) by the FDA. The two LBPs are MRx0005 and MRx0029 for the treatment of Parkinson's disease. Furthermore, the first-in-human Phase I trial of the LBPs is expected to commence in mid-2022.
2月22日，該公司宣佈FDA批准了兩種活性生物療法(LBPS)。這兩個LBP是用於治療帕金森病的MRx0005和MRx0029。此外，LBPS的第一階段人類試驗預計將於2022年年中開始。
